GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its ...

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Hims & Hers Health, Inc. (HIMS) Alleged “Deceptive” Marketing of Wegovy® Triggers Securities Class Actions – HIMS Investors with Losses Encouraged to Contact Hagens Berman ...

Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership Wegovy maker Novo faces fee demand after losing copycat drug lawsuit Ozempic copies restricted after US judge denies ...